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Abstract
AIM: Elevation of alanine aminotransferase (ALT) level is
commonly seen among patients suffering from severe
acute respiratory syndrome (SARS). We report the
progression and clinical significance of liver derangement
in a large cohort of SARS patient.
METHODS: Serial assay of serum ALT was followed in
patients who fulfilled the WHO criteria of SARS. Those
with elevated ALT were compared with those with normal
liver functions for clinical outcome. Serology for hepatitis
B virus (HBV) infection was checked. Adverse outcomes
were defined as oxygen desaturation, need of intensive
care unit (ICU) and mechanical ventilation and death.
RESULTS: Two hundred and ninety-four patients were
included in this study. Seventy (24%) patients had elevated
serum ALT on admission and 204 (69%) patients had
elevated ALT during the subsequent course of illness. Using
peak ALT >5×ULN as a cut-off and after adjusting for
potential confounding factors, the odds ratio of peak ALT
>5× ULN for oxygen desaturation was 3.24 (95%CI
1.23-8.59, P = 0.018), ICU care was 3.70 (95%CI
1.38-9.89, P = 0.009), mechanical ventilation was 6.64
(95%CI 2.22-19.81, P = 0.001) and death was 7.34
(95%CI 2.28-24.89, P = 0.001). Ninety-three percent of
the survived patients had ALT levels normalized or were
on the improving trend during follow-up. Chronic hepatitis
B was not associated with worse clinical outcomes.
CONCLUSION: Reactive hepatitis is a common complication
of SARS-coronavirus infection. Those patients with severe
hepatitis had worse clinical outcome.
© 2005 The WJG Press and Elsevier Inc. All rights reserved.
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INTRODUCTION
Severe acute respiratory syndrome (SARS) is caused by a
novel coronavirus (SARS-coronavirus, SARS-CoV) infecting
primarily the lung and the enteric tract[1-9]. Up to August
2003, there were 8 422 reported cases worldwide and 916
cases died of this condition[10]. Although the outbreak of
SARS is currently under control, the source of SARS-CoV
has not been identified and the threat of SARS returning in
winter persists.
Case series in Hong Kong and Toronto indicated that
SARS is not merely a respiratory disease. Diarrhea and
bleeding diathesis had also been reported in patients infected
by SARS-CoV[11,12]. In our previous report, SARS-CoV was
found in biopsy of small intestine and colon of patients
with diarrhea[11]. Deranged liver functions were reported in
22-56% of patients at the time of hospital admission[13-17].
In a previous study, it has also been suggested that co-
infection with hepatitis B virus (HBV) is associated with
more severe respiratory disease[18]. The cause of impaired
liver function, its clinical implication and association with
HBV co-infection have not been fully explored.
In this study, we follow the natural course of hepatic
involvement in SARS. The impact of liver derangement
and chronic HBV infection on the clinical outcome of SARS
patients is revisited.
MATERIALS AND METHODS
Patients
Patients in the present study were collected from a university
medical center (Prince of  Wales Hospital) and a community
hospital (Princess Margaret Hospital) designated to look
after SARS patients during the outbreak in Hong Kong. All
patients fulfilled the case definitions of  SARS by the World
Health Organization, i.e., temperature above 38 ℃, difficulty
in breathing and cough, pneumonic changes on chest X-ray
or high-resolution computed tomography, and contact
history with SARS patients[19]. All patients were initially
treated with empirical antibiotics including cefotaxime and
clarithromycin (or levofloxacin) to cover common pathogens
causing community-acquired pneumonia. Oseltamivir
(Tamiflu) was also given to treat possible influenza
infection when little was known about SARS during the
early phase of the outbreak. If fever persisted for more
than 48 h, all patients received corticosteroids and ribavirin
treatment. The choice of corticosteroids was intravenous
hydrocortisone 100 mg every 8 h or oral prednisolone
1 mg/kg body weight per day. Ribavirin was given at 400 mg
every 8 h intravenously or 1 200 mg thrice a day orally.
Pulse intravenous methylprednisolone (500-1 000 mg/d),
up to a maximum dose of 3 g, was given when there were
signs of radiological or clinical deterioration. Patients,
with oxygen saturation that fell below 90% at room air,
were offered supplementary oxygen through nasal cannula.
Those who required more than 4 L/min oxygen would be
transferred to intensive care unit (ICU) for close monitoring.
Mechanical ventilation by CPAP was implemented, when
patients could not achieve 90% oxygen saturation despite
receiving 5 L/min oxygen or more. All patients were kept
in hospital for monitoring for at least 3 wk before
discharge. Liver enzymes were checked every 1-3 d during
hospital stay, on discharge and on follow-up visits. Clinical
outcomes were assessed at least 8 wk after the admission
of patients.
Serological assays
The level of anti-coronavirus IgG antibody was measured
by immunofluorescence assay. Paired sera from acute (taken
within 7 d after the onset of fever) and convalescent (taken
14-21 d after the onset of fever) blood samples were tested
at serial two-fold dilutions starting from 1:40. Positive
serological evidence of coronavirus infection was defined
as either having a seroconversion or ≥four-fold rise in
antibody titer. Hepatitis B surface antigen (HBsAg)
and hepatitis C antibodies (anti-HCV) were tested by
commercially available enzyme-linked immunosorbent assay
kits (Abbott GmBH Diagnostika, Wiesbaden-Delkenheim,
Germany). Hepatitis B e antigen (HBeAg) and antibodies
to hepatitis B e antigen (anti-HBe) were measured by ELISA
(Sanofi Diagnostics, Pasteur, France).
Data analysis
Continuous variables were expressed as mean±SD for
normal distribution data and median (range) if  the distribution
was skewed. Statistical analysis was performed by SPSS (version
11.0, Chicago). Categorical variables were compared by 2
test and continuous variables by Student’s t test or Mann-
Whitney U test as appropriate. Adverse clinical outcomes
were defined as need of oxygen desaturation requiring
oxygen supplementation, ICU admission, mechanical
ventilation, liver decompensation and mortality. Liver
decompensation was defined as development of hepatic
encephalopathy associated with elevated serum bilirubin
(>51 mmol/L) and prolonged prothrombin time (>16 s).
As the reference ranges of  alanine aminotransferase (ALT)
levels were different between the two hospitals, ALT levels
were expressed as folds of increase above the upper limit
of  normal (ULN) in individual laboratories. The relationships
of  peak ALT levels and various adverse clinical outcomes
were compared by receiver operator characteristic curve.
Baseline clinical characteristics with a P value <0.1 for
adverse clinical outcomes on comparing patients with high
peak ALT levels vs. those with lower ALT levels were
adjusted by multivariate logistic regression analysis. All
statistical tests were two-sided. P value <0.05 was statistically
significant.
RESULTS
Clinical characteristics
Two hundred and ninety-four patients including 126 male
(43%) and 168 female were included in this study. The
median age of this cohort was 36 years, range 12-83 years.
Two hundred and forty-three patients had paired blood
samples checked for SARS-CoV serology and all had positive
results. These patients were admitted on the third (range
0-11) day after the onset of fever. Thirty (10%) patients
were found to have positive HBsAg and 214 patients had
negative HBsAg. In 50 cases, HBsAg status was not checked
during hospitalization. All patients in the Prince of  Wales
cohort had negative anti-HCV antibodies, and 7 of  12 HBV-
infected patients had positive HBeAg. Anti-HCV and
HBeAg status were not routinely monitored in the Princess
Margaret Hospital cohort. Lamivudine (100 mg/d) was
commenced in 20 of the 30 chronic hepatitis B patients on
or before the commencement of corticosteroid treatment
and was continued thereafter. Two chronic hepatitis B
infected patients had co-existing liver cirrhosis. One of them
had inoperable multi-focal hepatocellular carcinoma and
the other was admitted for bleeding esophageal variceal.
Forty-one (14%) patients had other co-morbid illnesses
including hypertension (12), diabetes mellitus (5), end-stage
renal failure (2), chronic rheumatic heart disease (2), ischemia
heart disease (2), sick sinus syndrome (1), atrial fibrillation
(1), asthma (1), chronic obstructive airway disease (1),
bronchiectasis (1), old pulmonary tuberculosis (1), previous
cerebrovascular accident (1), autism (1) and pregnancy (1).
Overall, 141 (48%) patients had oxygen desaturation,
50 (17%) required admission to ICU, 33 (11%) patients
required mechanical ventilation, and 27 (9%) patients died.
None of the patients developed liver decompensation after
contracting SARS. All mortalities were due to respiratory
failure related to SARS with or without sepsis and multi-
organ failure. The outcome of the studied cohort is
summarized in Figure 1.
Liver enzyme derangement on admission
Seventy (24%) patients, including 15 chronic hepatitis
B-infected patients, had elevated ALT levels on admission.
The median ALT levels on admission was 0.55 (0.16-26.09)
times upper limit of  laboratory normal. The proportion of
patients with different ALT levels, serum bilirubin and
prothrombin time on admission are shown in Figure 2. Two
chronic hepatitis B infected patients were admitted with
icteric flare-up of chronic hepatitis B on lamivudine treatment
and contracted SARS during their hospital stay. They had
elevated serum bilirubin to more than 150 mmol/L and
one of them had prolonged prothrombin time to 17 s. All
other patients who had elevated ALT levels had normal
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serum bilirubin levels and had no evidence of hepatic
decompensation.
Progression of liver derangement on follow-up
During the course of illness, 204 (69%) patients, including
23 HBsAg-positive patients, had elevated ALT levels. Majority
of  patients had ALT levels elevated at day 5-7 from fever
onset and ALT peaked at the end of  second week (Figure 3).
The median peak ALT levels was 1.53 (0.28-316.25) times
ULN. The proportion of  patients with different peak ALT
levels, serum bilirubin and prothrombin time are shown in
Figure 2. Twenty-eight (9.5%) patients had ALT raised to
over 5× ULN; among them 7 patients had elevated serum
bilirubin (median 83 mmol/L, range 48-231 mmol/L) and
10 patients had elevated prothrombin time (median 20 s,
range 14-56 s). Among the 138 patients in the Prince of  Wales
Hospital cohort, the median peak alkaline phosphatase (ALP)
level was 0.78 (range 0.31-19.38) times ULN and 40 (29%)
patients had experienced elevated ALP during the course of
illness. None of these patients developed hepatic encephalopathy.
Seven of the 28 (25%) patients died of SARS and multi-
organ failure. On the other hand, only 5 of 89 (6%) patients
who had persistently normal ALT died.
The area under the receiver operator characteristic curve
of  peak ALT for oxygen desaturation, need of  ICU care,
mechanical ventilation and mortality were 0.70 (95%CI
0.64-0.75; P<0.001), 0.72 (95%CI 0.65-0.79; P<0.001), 0.71
(95%CI 0.62-0.80, P<0.001) and 0.65 (95%CI 0.54-0.76,
Figure 2  A: Proportion of patients with different ALT levels at initial visit (n = 294), at peak ALT (n = 293; 1 missing data) and on last follow-
up (n = 264; 27 patients died, 3 missing data). ALT normal    , 1–2× ULN    , 2–5× ULN    , >5× ULN    . B: Proportion of patients with different
serum bilirubin levels at initial visit (n = 294) and at peak bilirubin (n = 293, 1 missing data). <35 µmol/L    , 35–51 µmol/L    , >51 µmol/L    .
C: Proportion of patients with different prothrombin time at initial visit (n = 293, one missing data) and at peak prothrombin time (n = 283,
11 missing data). <12 s    , 12–16 s    , >16 s    .
Figure 1  Clinical outcomes of patients included in the study. ALT, alanine aminotransferase. 1One patient did not have serial ALT results.
2Two patients did not have follow-up ALT results after discharge.
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P = 0.011), respectively. Using the coordinate of  peak ALT
>5× ULN, the sensitivity and specificity for any adverse
outcomes were 15-27% and 93-95% respectively. Patients
who had peak ALT over 5× ULN had significant male
predominance, more co-existing co-morbid conditions, more
chronic hepatitis B patients and marginally higher serum
creatinine levels as compared to those who had lower peak
ALT levels (Table 1). Using peak ALT >5×ULN as a cut-
off and after adjusting these potential confounding factors,
the odds ratio of  peak ALT >5×ULN for oxygen
desaturation was 3.24 (95%CI 1.23-8.59, P = 0.018), ICU
care was 3.70 (95%CI 1.38-9.89, P = 0.009), mechanical
ventilation was 6.64 (95%CI 2.22-19.81, P = 0.001) and
death was 7.34 (95%CI 2.28-24.89, P = 0.001).
Excluding 27 patients who died and 3 patients who had
no follow-up ALT results, 84 of  264 (32%) patients had
persistently normal ALT levels during the entire course of
illness. Among the 180 patients who had elevated ALT levels,
128 (71%) had ALT subsequently normalized and 37 (21%)
patients had ALT on downward trend at the last follow-up
visit. The remaining 8% of  patients still had elevated ALT
levels on the last follow-up.
Co-infection with hepatitis B virus
Two of  the 30 HBsAg-positive patients died despite
lamivudine treatment. One patient was admitted for icteric
flare-up of chronic hepatitis B and the other had liver
cirrhosis admitted for esophageal variceal bleeding. Both
patients acquired SARS during their hospital stay. Seven
patients had persistently normal ALT levels throughout the
admission and follow-up visits (six were on lamivudine).
Twenty-one HBsAg-positive patients had elevated ALT
during the SARS illness. Among them, 10 patients (6 on
lamivudine) had transient elevation of  ALT which
subsequently returned to normal levels, 8 (5 on lamivudine)
had declining levels of  ALT and 3 patients (1 on lamivudine)
had persistently elevated ALT levels. In this series, co-
infection with viral hepatitis B was not associated with higher
peak ALT level, increased risk of  oxygen desaturation, ICU
admission, mechanical ventilation or mortality (Table 2).
Table 1  Univariate analysis of baseline clinical characteristics
among patients with peak ALT levels >5× ULN vs with patients with
peak ALT levels ≤5× ULN
         Peak ALT >5× ULN Peak ALT ≤5× ULN             P
Number of patients        28                 265
Age (yr)    40±14               39±15               0.68
Male  17 (61%)         109 (41%)            <0.001
Co-morbid   4 (14%)           37 (14%)               0.002
Hemoglobin (g/dL)  13.4±2.1           13.4 ±1.5               0.94
White cell count (×109/L)    5.3±2.3              5.0±2.0               0.49
Neutrophil (×109/L)    4.2±1.9              3.8±1.9               0.30
Lymphocyte (×109/L)    0.8±0.5              0.8±0.5               0.90
Platelet (×109/L)  146±53             151±53               0.64
Creatinine (mol/L)          83 (48–1 318)          79 (43–214)               0.09
HBsAg                  6/25 (24%)        24/218 (11%)            <0.001
Oxygen supplementation 21 (75%)           120 (45%)            <0.001
ICU care 11 (39%)             39 (15%)            <0.001
Mechanical ventilation   9 (32%)             24 (9%)               0.012
Death   7 (25%)             20 (8%)               0.017
Table 2  Clinical outcome of patients with and without chronic
hepatitis B
HBsAg positive       HBsAg negative P
Number of patients               30                   214
Peak ALT (×ULN)   2.2 (0.6–26.1)        1.5 (0.3–316.3)                 0.16
Oxygen supplementation       17 (57%)             104 (49%)                 0.68
ICU care         5 (17%)               30 (14%)                 0.70
Mechanical ventilation         3 (10%)               19 (9%)                 0.84
Death         2 (7%)               14 (7%)                 0.98
DISCUSSION
Although SARS is primarily a pulmonary disease, liver
derangement was commonly observed[13-17]. In this study,
approximately a quarter of  patients had elevated ALT on
admission, and a further 45% of  patients who had normal
ALT on admission had ALT elevation during the course of
illness. In a majority of  patients ALT levels started to elevate
towards the end of first week and peak at the end of second
week. High peak ALT level appears to be an independent
predictor of more severe illness and worse clinical outcome.
Most patients however had transient elevation of  ALT, which
normalize spontaneously with the recovery of  SARS.
The underlying cause for ALT elevation was uncertain
but several mechanisms were worth considering. Direct
pathogenic effect of SARS-CoV on the liver is unlikely due
to the failure of identification of SARS-CoV or specific hepatitis
features in the liver at autopsy in previous reports[20-23].
Elevated ALT might be related to the prescribed medications
including antibiotics and high dose ribavirin. As a quarter
of  patients had elevated ALT levels on admission well before
the prescription of drugs, drug treatment should not be the
cause of liver enzyme derangement in these patients.
Furthermore, many patients had ALT >5× ULN. This is
exceedingly rare with antibiotic and ribavirin given at these
dosages[24]. Although chronic hepatitis C virus infection has
only been excluded in about half of the cases in this series
(the Prince of  Wales Hospital cohort), the prevalence of
chronic hepatitis C is very low among the general population
in Hong Kong.
Figure 3  Median ALT and serum bilirubin levels of patients admitted
to Prince of Wales Hospital (n = 138) from the day of fever onset to
day 21 at hospital discharge. Both ALT and bilirubin levels were
expressed as folds of ULN. Only patients who had at least one el-
evated ALT level during admission were included (n=104). ULN, up-
per limit of laboratory normal; solid line, serum ALT; broken line,
serum bilirubin.
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We believe that the elevation of  liver enzyme is a reactive
response towards SARS-CoV infection[25]. The hepatic acute
phase response involving cytokine release from inflammatory
cells is a defense reaction of the body against the causative
agent to protect the vital functions of the liver[26]. The liver
enzyme elevation in SARS is not typical of cholestasis
secondary to sepsis as majority of patients did not have
accompanied elevation of ALP. This is usually a transient
reaction and therefore majority of  patients have ALT levels
returned to normal after recovery.
Although SARS-CoV is not a direct cause of liver injury,
results from this study indicated that gross liver enzyme
elevation, as indicated by high peak ALT levels, is an
independent factor associated with poor clinical outcome.
Peak ALT over 5×ULN increased the risk of  mortality by
seven-folds. Although age and co-morbid illnesses had been
found to have significant negative impact on prognosis in
SARS[6,13,18,27], in this study, the age of patients did not differ
significantly between those with high or low peak ALT levels.
Baseline ALT levels have not been found to be associated
with any adverse clinical outcome in the past probably
because of  the delayed elevation of  ALT levels in most
patients. In fact most immunological damage of SARS in
the lungs occurred in the second week of the illness[12,28].
The level of  ALT elevation may reflect the severity of
acute phase response, which in turn may reflect the severity
of  tissue damage in SARS[17]. We believe that the elevated
ALT can serve as a surrogate marker to predict the clinical
outcome of SARS.
We did not find any difference in various adverse clinical
outcomes among chronic hepatitis B patients as compared
to the HBsAg-negative patients. In our cohort, 16 (53%)
chronic hepatitis B patients had elevated ALT levels upon
admission and two of them suffered from icteric flare-up
of hepatitis. Perhaps those patients who suffered from
severe flare-up of hepatitis or decompensated liver cirrhosis
might have a higher risk of mortality[29]. Lamivudine was
not prescribed to one-third of the patients but none of
them died or developed hepatic decompensation.
In conclusion, we found that elevation of transaminase
is a very common feature in SARS. The ALT elevation is usually
transient and likely to be reactive in nature. Co-infection
with HBV in the absence of liver cirrhosis or reactivated
hepatitis does not affect the natural course of the disease.
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